Pasquale Benedetto

University of Miami — United States

Medicine · Health Sciences

25h-index2.7kcitations96works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(20), Cancer Treatment and Pharmacology(13), Soft tissue tumor case studies(13), Salivary Gland Tumors Diagnosis and Treatment(10), Colorectal Cancer Treatments and Studies(10)

Publications95 total

Case Report: Somatic malignancy classified as Wilms tumor arising within an immature teratoma
Frontiers in Oncology·2025Open Access
Severe Lymphoma-Associated Hemophagocytic Syndrome in a Young Woman
Cureus·2024· 1 citedOpen Access
Neoadjuvant Intra-arterial Cytoreductive Chemotherapy Improves Outcomes in Lacrimal Gland Adenoid Cystic Carcinoma
The Oncologist·2024· 3 citedOpen Access
Figure S1 from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Data from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Data from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
2023Open Access
Data from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Supplementary Data from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Data from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Supplementary Figure from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Figure S1 from A Phase I Clinical, Pharmacokinetic, and Pharmacodynamic Study of Weekly or Every Three Week Ixabepilone and Daily Sunitinib in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Data from Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in <i>CTNNB1</i> or <i>APC</i>: A Multi-institutional Retrospective Study
2023Open Access
Neoadjuvant Intra-Arterial Cytoreductive Chemotherapy for Lacrimal Gland Adenoid Cystic Carcinoma: A Long-Term Follow-up Study of a Trimodal Strategy
American Journal of Ophthalmology·2022· 21 citedOpen Access
page 1 of 5Next →

Frequent Co-authors

Bach Ardalan(9), Lynn G. Feun(9), Niramol Savaraj(9), Stephen P. Richman(8), Stuart Waldman(7), David T. Tse(7), Kasi S. Sridhar(6), K. S. Sridhar(6), William J. Feuer(5), Alan S. Livingstone(5), K. Rajender Reddy(4), Louise Morrell(4), Atif Hussein(4), Robert Duncan(4), Sander R. Dubovy(3), Joé U. Levi(3), Tauseef Ahmed(3), Alan Yagoda(3), Robin C. Watson(3), Awtar Krishan(3)